Sanofi Net Total Equity Issued/Repurchased 2010-2025 | SNY
Sanofi annual/quarterly net total equity issued/repurchased history and growth rate from 2010 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- Sanofi net total equity issued/repurchased for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Sanofi net total equity issued/repurchased for the twelve months ending March 31, 2025 was $-0.427B, a 46.13% decline year-over-year.
- Sanofi annual net total equity issued/repurchased for 2024 was $-0.124B, a 71.11% decline from 2023.
- Sanofi annual net total equity issued/repurchased for 2023 was $-0.431B, a 32.31% increase from 2022.
- Sanofi annual net total equity issued/repurchased for 2022 was $-0.326B, a 40.4% increase from 2021.
Sanofi Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$-124 |
| 2023 |
$-431 |
| 2022 |
$-326 |
| 2021 |
$-232 |
| 2020 |
$-707 |
| 2019 |
$171 |
| 2018 |
$-1,091 |
| 2017 |
$-2,083 |
| 2016 |
$-2,880 |
| 2015 |
$-1,344 |
| 2014 |
$-1,489 |
| 2013 |
$-843 |
| 2012 |
$-228 |
| 2011 |
$-1,394 |
| 2010 |
$-327 |
| 2009 |
$234 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$130.557B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
